The new study looked at how the drug performed in about 95 per cent of trial patients who continued on the treatment. After three years, Leqembi slowed cognitive decline by 31 per cent compared to what would be expected in similar patients who did not receive treatment.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/X97dBbW
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment